| Aimovig (erenumab-aooe) / Amgen, Novartis |
2018-003943-46: Investigation on the effect and tolerability of erenumab in posttraumatic headache Undersøgelse af effekten og tolerabilitet af erenumab ved posttraumatisk hovedpine |
|
|
| Not yet recruiting | 2 | 100 | Europe | Aimovig | Danish Headache Center, Novartis | Post-traumatic headache Post-traumatisk hovedpine, Headache after concussion Hovedpine efter et hovedtraume, Diseases [C] - Nervous System Diseases [C10] | | | | |
2020-004399-16: Efficacy of Erenumab in the preventive treatement of chronic cluster headache (painful headache attacks):A 10 week clinical trial, which will be performed at multiple (=multicentric) trial centers (e.g. hospitals, doctors office).Patients will be assigned / allocated on random basis (=randomization) to either the experimental group (Erenumab) or control group (Placebo). Neither the patient nor the treating physician knows if the patient receives Erenumab or Placebo (double-blind) |
|
|
| Not yet recruiting | 2 | 118 | Europe | Injection, Aimovig | Charité - Universitätsmedizin Berlin, Novartis Pharma GmbH | chronic cluster headache, Recurrent, severe, painful (one-sided) headache attacks, Diseases [C] - Nervous System Diseases [C10] | | | | |
2019-003971-20: An open label study to evaluate the efficacy and tolerability of erenumab in the management of persistent redness and flushing in rosacea |
|
|
| Not yet recruiting | 2 | 30 | Europe | Injection, Aimovig (Erenumab) | Rigshospitalet Glostrup, Novartis, Rigshospitalet Glostrup | Rosacea, Rosacea, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2019-000848-95: Investigation on the effect and tolerability of erenumab in trigeminal neuralgia Undersøgelse af effekten og tolerabilitet af erenumab ved trigeminusneuralgi |
|
|
| Not yet recruiting | 2 | 80 | Europe | Solution for injection, Aimovig | Dansk Hovedpine Center, Neurologisk Klinik, Rigshospitalet - Glostrup, Novartis | Trigeminal neuralgia Trigeminusneuralgi, Trigeminal neuralgia is a painful neuropathic disorder characterized by stabbing, intense, touch-evoked pain attacks in the face. Trigeminusneuralgi er en alvorlig ansigtssmertelidelse med unilaterale svære stikkende, jagende og/eller skarpe smerter af få sekunders varighed der er lokaliseret i ansigtet., Diseases [C] - Nervous System Diseases [C10] | | | | |
| Completed | 2 | 101 | Europe | Erenumab, AMG 334, Placebo | Charite University, Berlin, Germany | Cluster Headache, Trigeminal Autonomic Cephalalgias, Headache Disorders, Primary, Brain Disease | 09/23 | 09/23 | | |
NCT04884763: Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder |
|
|
| Completed | 2 | 30 | US | Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments, Aimovig®, Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments, Placebo | Indiana University, Novartis Pharmaceuticals | Temporomandibular Disorder | 01/24 | 01/24 | | |
NCT04098250: Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH |
|
|
| Recruiting | 2 | 112 | US | Erenumab, Aimovig, Placebo | Mayo Clinic, University of Arizona, Translational Genomics Research Institute, Arizona State University, Phoenix VA Health Care System, United States Department of Defense, Amgen | Post-Traumatic Headache | 08/24 | 08/24 | | |
| Recruiting | 2 | 40 | US | Siltuximab, Sylvant, Erenumab-Aooe, Aimovig, Siltuximab Matching Placebo, Normal Saline, Erenumab-Aooe Matching Placebo | Massachusetts General Hospital, United States Department of Defense, Recordati Rare Diseases | Schwannomatosis, Schwannomas, Pain, Chronic | 03/26 | 11/27 | | |
NCT05049057: Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI |
|
|
| Recruiting | 2 | 404 | US | Erenumab 140 Mg/mL Subcutaneous Solution, Aimovig, Placebo | Henry M. Jackson Foundation for the Advancement of Military Medicine | Posttraumatic Headache, Mild Traumatic Brain Injury | 05/26 | 05/27 | | |
